Kailera Therapeutics KLRA
NASDAQ KLRA
$13.27 +0.06 (+0.45%)
At close: Nov 13, 2026 · 4:00 PM EST

Kailera Therapeutics (KLRA) Sale and Maturity of Investments (2025 - 2026)

Updated

Kailera Therapeutics' Sale and Maturity of Investments - Total came in at $147.89 million for Q3 2026, up 113.7% from $69.21 million a year earlier and up 24.5% from the prior quarter.

Analysis

Kailera Therapeutics (KLRA) Sale and Maturity of Investments (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Sep 30, 2026, Kailera Therapeutics reported Sale and Maturity of Investments - Total of $402.41 million; for FY2025, it was $141.65 million.

  • Business Quant data shows KLRA's Sale and Maturity of Investments - Total at $118.79 million (Q2 2026), $71.3 million (Q1 2026) and $64.44 million (Q4 2025) in the three quarters before Q3 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 308.00 Mn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn -
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 405.00 Mn
5 Novartis Ag 306.35 Bn 279.93 Bn - 88.00 Mn
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn -
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 2.53 Bn
10 Kailera Therapeutics 1.72 Bn -1.16 Bn - 147.89 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 147.89 Mn
Jun 30, 2026 118.79 Mn
Mar 31, 2026 71.30 Mn
Dec 31, 2025 64.44 Mn
Sep 30, 2025 69.21 Mn
Jun 30, 2025 8.00 Mn
API Access

Kailera Therapeutics Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=KLRA&period=max&api_key=YOUR_API_KEY